By Mill Chart
Last update: Apr 15, 2024
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Ticker | Change | Comment |
---|---|---|
EAF | -11.76% | GRAFTECH INTERNATIONAL LTD's (NYSE:EAF) shares fell 11.76% to $1.5 during Monday's after hours session. In the last 6 months the stock lost 50.0%. |
CLDI | -11.67% | CALIDI BIOTHERAPEUTICS INC's (NYSEARCA:CLDI) shares declined by 11.67% to $0.53 during Monday's after-hours session. NYSEARCA:CLDI had a challenging day, closing -13.64% lower during the regular session, and the downward trend continues in the after-hours session. |
DBGI | -10.0% | Price volatility persists as NASDAQ:DBGI closed the regular session with a %ABSPERF% loss, and the downward trend continues in the after-hours session. DIGITAL BRANDS GROUP INC released earnings today. In the last month the share price increased with 25.0%. |
PSTX | -9.88% | POSEIDA THERAPEUTICS INC's (NASDAQ:PSTX) stock price is showing a decline of 9.88% to a price of $2.19 during the after-hours session. NASDAQ:PSTX had a challenging day, closing -10.99% lower during the regular session, and the downward trend continues in the after-hours session. |
HRYU | -7.53% | Today's after-hours session sees a continuation of the %ABSPERF% decrease earlier in the day for NASDAQ:HRYU. In the last month the share price increased with 59.64%. |
KAVL | -7.3% | After today's 136.0% drop, NASDAQ:KAVL shows further decline during today's after-hours session with a 7.3% decrease. After registering a 136.0% gain earlier today, NASDAQ:KAVL is experiencing a 7.3% decline in today's after-hours session. |
MITK | -6.88% | MITEK SYSTEMS INC's (NASDAQ:MITK) stock price is declining with 6.88% to a price of $13.81. MITEK SYSTEMS INC released earnings Yesterday. A press release (Mitek Reports Fiscal 2024 First Quarter Financial Results and Provides Preliminary Second Quarter Revenue Results) was released earlier today. |
SNGX | -6.36% | Following a 21.73% loss in the regular session, NASDAQ:SNGX exhibits further decline during today's after-hours session. Today's after-hours session indicates a reversal in NASDAQ:SNGX's earlier 21.73% gain, with prices exhibiting heightened volatility. |
LGVN | -5.12% | The after-hours session reflects NASDAQ:LGVN's ongoing correction after experiencing a 73.37% loss in the regular trading hours. Price movements remain volatile as NASDAQ:LGVN gives back 73.37% of its earlier gains in the after-hours session. |
SPEC | -4.82% | Following a 26.73% loss in the regular session, NASDAQ:SPEC exhibits further decline during today's after-hours session. Despite a strong 26.73% gain earlier today, NASDAQ:SPEC is experiencing a reversal in after-hours trading, with prices declining by 4.82%. |
To see the full list of after hours losers you can use our after hours losers page.
POSEIDA THERAPEUTICS INC
NASDAQ:PSTX (5/9/2024, 3:30:01 PM)
After market: 2.71 0 (0%)2.71
0 (0%)
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics, Inc. (NASDAQ: PSTX, President and CEO:...
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell therapy and genetic medicines company advancing a new class of treatments for...
Pre-market stock movers are worth diving into on Tuesday as we check out all of the biggest changes and the news behind them!
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
PSTX stock results show that Poseida Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Poseida Therapeutics (NASDAQ:PSTX) just reported results for the fourth quarter...
Lead asset P-BCMA-ALLO1 Phase 1 clinical trial data presented at ASH 2023 demonstrated 82% ORR and favorable emerging safety and reliability profile Initiated...
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...